An interventional study of Free genetic testing and counseling group and IGNITE-TX Group in Gynecologic Cancer, Ovary Cancer and Pancreatic Cancer, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2023, is one of 17 with no phase, and was the 30th registered.
62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.
Browse Hereditary Breast and Ovarian Cancer Syndrome studies →7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 35+ · Women only
Georgetown University · Sites in United States
Ages 18–74 · Women only
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
University of Kansas Medical Center · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 150 across 43 interventional studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.
Median enrollment 157 across the 23 interventional studies, 440 across the 12 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 35 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 3 studies filed under Hereditary Breast and Ovarian Cancer Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02302742University of Kansas Medical CenterTriple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry | 2026-12 |
| NCT06892275Georgetown UniversityThe FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | 2027-06 |
| NCT05677048M.D. Anderson Cancer CenterFeasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing.
The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.
Primary Objectives:
The primary objectives of this study are to assess the study feasibility by estimating:
Secondary Objectives:
The secondary objectives of this study are to:
Exploratory Objectives:
The exploratory objectives in this study are to estimate:
62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.
This study's enrollment of 205 is above the median of 150 across 43 interventional studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.
Browse Hereditary Breast and Ovarian Cancer Syndrome studies →M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
Compared within Hereditary Breast and Ovarian Cancer Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ovarian Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Probands
Inclusion Criteria:
Exclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Participants (probands, those with a hereditary cancer syndrome) are sent a family letter to share with relatives. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing. Relatives of probands randomized to the usual care arm will have access to the family letter if probands decide to share it with them, and will receive study surveys. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic testing
Enrolled relatives will receive a letter and baseline survey with information to contact the tele-genetics company to arrange free genetic counseling and testing. This letter will be given to the relatives directly by the study
Behavioral: Free genetic testing and counseling group · Behavioral: IGNITE-TX Group · Behavioral: IGNITE-TX and free genetic testing and counseling group
Relatives of probands randomized to the IGNITE-TX intervention will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX "Hub" (access online educational material through a platform). Relatives will have also access services of a family genetic navigator. Study investigators and navigators will not directly provide genetic counseling and/or testing in this arm
Behavioral: Free genetic testing and counseling group · Behavioral: IGNITE-TX Group · Behavioral: IGNITE-TX and free genetic testing and counseling group
Relatives randomized to this arm will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX "Hub" (access online educational material through a platform) and information to contact the tele genetics company. This arm will receive both the IGNITE-TX Intervention and access to free genetic testing and counseling services, as well as access to assistance from family genetic navigator
Behavioral: Free genetic testing and counseling group · Behavioral: IGNITE-TX Group · Behavioral: IGNITE-TX and free genetic testing and counseling group
Option to access no-cost telegenetic counseling and genetic testing
Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator
Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
Measure enrollment of probands and at-risk relatives over a 6-month period
Time frame: Up to 6 months
Measure response rate to baseline and follow-up surveys by probands and at-risk relatives
Time frame: Up to 6 months
Started Apr 2023 (actual). Primary completion is estimated for Oct 2027, 54 months after the start.
Of 23 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's planned 54 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hereditary Breast and Ovarian Cancer Syndrome →